Triple-negative breast cancer (estrogen receptor negative, progesterone receptor negative and HER2 negative) is a particularly high-risk breast cancer which does not receive specific therapy targeting these proteins. We report the case of a 23-year-old patient diagnosed with triple-negative breast cancer of the left breast with a family history of breast cancer and carrying a BRCA1 mutation. The classification of breast cancer based on genomic data is required to allow us to optimize therapies and improve the management of breast cancer patients.
No takes yet. Share an insight, caveat, or question.
Belhaouz et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: